Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and cilofexor/firsocostat in compensated cirrhosis due to NASH
2021-001445-12Phase 2Active
- Sponsor
- Gilead Sciences
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of semaglutide, cilofexor and firsocostat in metabolic dysfunction-associated steatohepatitis (MASH) and Cirrhosis (4 arms), sponsored by Gilead Sciences. Primary endpoint: Coprimary endpoints. Started Oct 2021; status: active.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on 2021-001445-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001445-12.